Jilin Aodong Pharmaceutical Group Co., Ltd. Stock price

Equities

000623

CNE000000719

Pharmaceuticals

End-of-day quote Shenzhen S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
14.36 CNY +0.21% Intraday chart for Jilin Aodong Pharmaceutical Group Co., Ltd. -4.07% -5.15%
Sales 2023 * 3.45B 477M Sales 2024 * 4.12B 570M Capitalization 17.26B 2.39B
Net income 2023 * 2.06B 285M Net income 2024 * 2.33B 322M EV / Sales 2023 * 5 x
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * 4.19 x
P/E ratio 2023 *
8.11 x
P/E ratio 2024 *
7.16 x
Employees 5,399
Yield 2023 *
-
Yield 2024 *
-
Free-Float 71.21%
More Fundamentals * Assessed data
Dynamic Chart
Tranche Update on Jilin Aodong Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on September 21, 2023. CI
Jilin Aodong Pharmaceutical Group Co., Ltd.'s Equity Buyback announced on September 21, 2023, has closed with 9,015,780 shares, representing 0.8% for CNY 150 million. CI
Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Chinese listed firms used endangered animal parts as ingredients -report RE
Three listed Chinese firms used endangered animal parts as ingredients- report RE
Tranche Update on Jilin Aodong Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on September 21, 2023. CI
Jilin Aodong Pharmaceutical Group Co., Ltd. announces an Equity Buyback for CNY 150 million worth of its shares. CI
Jilin Aodong Pharmaceutical Group Co., Ltd. authorizes a Buyback Plan. CI
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. cancelled the acquisition of Beijing Langyan Life Technology Holdings Co., Ltd. from a group of shareholders. CI
Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Jilin Aodong Yanbian Pharmaceutical Co., Ltd. announced that it expects to receive CNY 200 million in funding from Jilin Aodong Pharmaceutical Group Co., Ltd. CI
Jilin Aodong Pharmaceutical Group Co., Ltd. Elects Liang Biming as Independent Director CI
Aodong Medicine's Unit Gets Registration Certificate for 16 Formula Tablets MT
Jilin Aodong Pharmaceutical Group Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on July 7, 2023 CI
Jilin Aodong Pharmaceutical Group Co., Ltd Approves the Profit Distribution Proposal for 2022 CI
More news
1 day+0.21%
1 week-4.07%
Current month-5.40%
1 month-4.01%
3 months-5.34%
6 months-16.80%
Current year-5.15%
More quotes
1 week
14.28
Extreme 14.28
14.63
1 month
14.28
Extreme 14.28
15.30
Current year
13.13
Extreme 13.13
15.66
1 year
13.13
Extreme 13.13
18.17
3 years
13.13
Extreme 13.13
19.90
5 years
13.13
Extreme 13.13
19.90
10 years
11.45
Extreme 11.4462
35.62
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 97-12-31
Director of Finance/CFO 47 04-04-30
Director of Finance/CFO 50 99-06-30
Members of the board TitleAgeSince
Chairman 71 93-01-31
Chief Executive Officer 61 97-12-31
Chairman 57 00-09-30
More insiders
Date Price Change Volume
24-03-28 14.36 +0.21% 9,532,032
24-03-27 14.33 -0.90% 8,954,162
24-03-26 14.46 +0.49% 8,287,771
24-03-25 14.39 -1.44% 12,854,440
24-03-22 14.6 -2.47% 18,393,130

End-of-day quote Shenzhen S.E., March 27, 2024

More quotes
Jilin Aodong Pharmaceutical Group Co., Ltd. specializes in the manufacturing and marketing of pharmaceutical products. Besides, the group offers food products. Net sales break down by activity as follows: - sale of pharmaceutical products (89.4%); - sale of food products (6.8%); - other (3.8%). All sales are in China.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
14.36 CNY
Average target price
22.67 CNY
Spread / Average Target
+57.87%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Jilin Aodong Pharmaceutical Group Co., Ltd. - Shenzhen S.E.